Daxor Corporation (NASDAQ:DXR) Short Interest Update

Daxor Corporation (NASDAQ:DXR) was the target of a large drop in short interest in the month of June. As of June 15th, there was short interest totaling 2,083 shares, a drop of 66.2% from the May 31st total of 6,164 shares. Approximately 0.1% of the shares of the company are sold short. Based on an average daily volume of 2,060 shares, the days-to-cover ratio is currently 1.0 days.

Daxor Price Performance

Shares of NASDAQ:DXR traded down $0.30 during trading on Friday, reaching $10.02. 1,854 shares of the company’s stock traded hands, compared to its average volume of 2,168. Daxor has a fifty-two week low of $8.56 and a fifty-two week high of $14.76. The company has a 50-day simple moving average of $10.34 and a 200-day simple moving average of $11.48.

Daxor (NASDAQ:DXR) last announced its quarterly earnings results on Monday, March 2nd. The company reported ($0.10) earnings per share for the quarter.

Institutional Trading of Daxor

Institutional investors and hedge funds have recently made changes to their positions in the business. Aristides Capital LLC acquired a new position in shares of Daxor during the 1st quarter worth approximately $403,000. Crescent Grove Advisors LLC acquired a new stake in Daxor in the 1st quarter valued at $104,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management acquired a new stake in Daxor in the 1st quarter valued at $245,000. Nano Cap New Millennium Growth Fund L P purchased a new stake in Daxor in the 4th quarter worth $184,000. Finally, Osaic Holdings Inc. purchased a new stake in Daxor in the 2nd quarter worth $86,000. 1.34% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “hold (c)” rating on shares of Daxor in a research note on Wednesday. One analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy”.

Daxor Company Profile

Daxor Corporation is a medical diagnostics company focused on providing precise blood volume analysis to support patient management in critical care, surgical, cardiology and nephrology settings. The company’s core offering, the BVA‐100 Blood Volume Analyzer, employs radiolabeled albumin techniques to deliver accurate measurements of total blood volume, red cell mass and plasma volume. By quantifying a patient’s fluid status, Daxor aims to help clinicians tailor therapies for conditions such as anemia, heart failure and fluid overload.

In addition to the BVA‐100 analyzer, Daxor supplies reagent kits, calibration standards and software for data analysis and reporting.